Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial

Abstract

Background: Nicotinamide has been reported to protect against liver steatosis and metabolic imbalances in nonalcoholic fatty liver disease (NAFLD) in animal models. Objectives: The objective was to investigate the efficacy and safety of nicotinamide supplementation in diabetic NAFLD patients. Design: This is a prospective randomized controlled open label study. Methods: Seventy diabetic NAFLD patients were randomly assigned either to the nicotinamide group ( n = 35) who received nicotinamide 1000 mg once daily for 12 weeks in addition to their antidiabetic therapy or the control group ( n = 35) who received their antidiabetic therapy only. The primary outcome was improvement in steatosis score, while secondary outcomes included assessment of liver stiffness, liver enzymes, lipid profile, insulin resistance, serum malondialdehyde, serum adiponectin, and patients’ quality of life (QOL). Results: Only 61 patients completed the study; 31 in the nicotinamide group and 30 in the control group. Comparisons between groups and within groups revealed nonsignificant changes in steatosis and fibrosis scores. However, significant reduction was observed in liver enzymes with a median decrease in alanine transaminase of 26.6% versus 0.74% in nicotinamide and control groups, respectively. After 12 weeks of treatment, the nicotinamide group showed significantly lower levels of low-density lipoprotein cholesterol ( p value = 0.004), total cholesterol ( p value = 0.006), and insulin resistance marker ( p value = 0.005) compared with control. Serum triglycerides, malondialdehyde, and adiponectin levels were all comparable between the two groups. Regarding QOL, a significant improvement was detected in the total scores and the activity and fatigue domains scores. Conclusion: Nicotinamide at a dose of 1000 mg daily was tolerable, improved metabolic abnormalities and QOL of diabetic NAFLD patients with no effect on liver fibrosis or steatosis. Trial Registration: The study was registered at clinicaltrials.gov and given the ID number: ‘NCT03850886’. https://clinicaltrials.gov/ct2/show/NCT03850886 .

Nicotinamide supplementation alters plasma lipidomic profiles of peripartal dairy cows

“…Elevated plasma FFA levels are a sign of obesity and insulin resistance (Ormseth et al, 2013; Wakil & Abu‐Elheiga, 2009). Studies in mice and human have suggested that NAM or supplementation with a specific combination of metabolic cofactors was effective in improving insulin sensitivity (El‐Kady et al, 2022; Quesada‐Vazquez et al, 2021). Thus, perinatal NAM supplementation inhibits lipolysis and reduces the production of FFA, thereby relieving lipid metabolic pressure.…”

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice

“…Nicotinamide alleviates liver fibrosis or steatosis in patients with nonalcoholic fatty liver disease by elevating hepatic NAD + which inhibits lipogenesis and activates fatty acid oxidation ( 53 ). Urinary NAD + metabolism such as N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-3-carboxamide are increased in DIO mice ( 54 ) and are decreased by liraglutide ( 33 ).…”

Iron-Induced Hepatocarcinogenesis—Preventive Effects of Nutrients

“…Clinical research of niacin as a therapeutic for NAFLD is ongoing ( 119 ); however, whether niacin ameliorates HIO in patients with CLDs and prevents HCC needs to be addressed by future studies.…”